Targeting Tumor Microenvironment for Cancer Therapy
Open accessThe DOI matches its Crossref record; 209 of the 212 references it cites were found in a registry or an index.
Abstract
Cancer development is highly associated to the physiological state of the tumor microenvironment (TME). Despite the existing heterogeneity of tumors from the same or from different anatomical locations, common features can be found in the TME maturation of epithelial-derived tumors. Genetic alterations in tumor cells result in hyperplasia, uncontrolled growth, resistance to apoptosis, and metabolic shift towards anaerobic glycolysis (Warburg effect). These events create hypoxia, oxidative stress and acidosis within the TME triggering an adjustment of the extracellular matrix (ECM), a response from neighbor stromal cells (e.g., fibroblasts) and immune cells (lymphocytes and macrophages), inducing angiogenesis and, ultimately, resulting in metastasis. Exosomes secreted by TME cells are central players in all these events. The TME profile is preponderant on prognosis and impacts efficacy of anti-cancer therapies. Hence, a big effort has been made to develop new therapeutic strategies towards a more efficient targeting of TME. These efforts focus on: (i) therapeutic strategies targeting TME components, extending from conventional therapeutics, to combined therapies and nanomedicines; and (ii) the development of models that accurately resemble the TME for bench investigations, including tumor-tissue explants, “tumor on a chip” or multicellular tumor-spheroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Main properties of in vitro 2D and 3D culture systems [187,188]. CAF, Cancer-associated fibroblast; ECM, Extracellular matrix.](https://figures.cochat.ai/paper-figures/5beab1962bf5470fbdf9b87661e2bff6/targeting-tumor-microenvironment-for-cancer-therapy-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dense ECM, abnormal vasculature, and an acidified environment all contribute to decreased drug penetration [83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the microenvironment of healthy tissue, the TME has augmented deposition of proteins such as collagen and fibronectin, high cytokine levels, increased proportion of fibroblasts and immune cells, and is immunosuppressive [82,83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“agents that degrade and/or deconstruct the ECM should be used cautiously, as they may lead to the release of factors that promote tumor progression and induce metastasis [83].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Concerning the therapeutic outcome of such drugs, although they showed to improve patient survival, it has not been as great as expected, mostly related to the fact that patients stop responding or do not respond at all to these therapies, or even due to the side effects, for instance, the increased risk of arterial t…”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 3×
“Epithelial tumors display common features that allow for the setting of hallmarks that define cancer progression [7,8].”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“For this reason, tumors are frequently regarded as “wounds that never heal” [7,92].”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Rab27a and Rab27b control different steps of the exosome secretion pathway
Ostrowski, M., Carmo, N. B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C. F., Schauer, K., Hume, A. N., Freitas, R. P., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2000 · Cited by 2,750
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871 · cited 4×
“This response to low oxygen pressure levels includes regulation of genes involved in glucose metabolism, cell proliferation, angiogenesis, macrophage polarization into tumor-associated macrophages (TAM) and metastasis (reviewed in [11,19]).”
BackgroundInfluentialMicroenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 7×
“One example is the phase 1 trial NCT02665416 that evaluates the combination of Selicrelumab, a CD40 agonist, with Vanucizumab, a bispecific antibody that targets simultaneously ANGPT2 and VEGF-A versus the action of Selicrelumab with Bevacizumab, an anti-VEGF antibody, for treatment of advanced solid tumors.”
BackgroundInfluentialFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
ExoCarta: A Web-Based Compendium of Exosomal Cargo
Keerthikumar, S., Chisanga, D., Ariyaratne, D., Al Saffar, H., Anand, S., Zhao, K., Samuel, M., Pathan, M., Jois, M., Chilamkurti, N., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.09.019 · Cited by 1,452
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Microvesicles: mediators of extracellular communication during cancer progression
Muralidharan-Chari, V., Clancy, J. W., Sedgwick, A., & D'Souza-Schorey, C. (2010) · Journal of Cell Science · doi:10.1242/jcs.064386 · Cited by 950
3D tumor spheroids: an overview on the tools and techniques used for their analysis
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.002 · Cited by 929
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919
Ziello, J. E., Jovin, I. S., & Huang, Y. (2007) · PubMed Central · Cited by 895
Exosome Release Is Regulated by a Calcium-dependent Mechanism in K562 Cells
Savina, A., Furlán, M., Vidal, M., & Colombo, M. I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301642200 · Cited by 834
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 779
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
Bobrie, A., Krumeich, S., Reyal, F., Recchi, C., Moita, L. F., Seabra, M. C., Ostrowski, M., & Théry, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0925 · Cited by 645
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.006 · Cited by 641
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy
Izumi, H., Torigoe, T., Ishiguchi, H., Uramoto, H., Yoshida, Y., Tanabe, M., Ise, T., Murakami, T., Yoshida, T., Nomoto, M., et al. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00106-3 · Cited by 613
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy
Komohara, Y., Fujiwara, Y., Ohnishi, K., & Takeya, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.009 · Cited by 612
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Therapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
Park, J. E., Tan, H. S., Datta, A., Lai, R. C., Zhang, H., Meng, W., Lim, S. K., & Sze, S. K. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900381-mcp200 · Cited by 582
HIV Nef is Secreted in Exosomes and Triggers Apoptosis in Bystander CD4+ T Cells
Lenassi, M., Cagney, G., Liao, M., Vaupotič, T., Bartholomeeusen, K., Cheng, Y., Krogan, N. J., Plemenitaš, A., & Peterlin, B. M. (2010) · Traffic · doi:10.1111/j.1600-0854.2009.01006.x · Cited by 543
The Biology of Cancer Exosomes: Insights and New Perspectives
Ruivo, C. F., Adem, B., Silva, M., & Melo, S. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0994 · Cited by 538
3D Cell Culture: A Review of Current Approaches and Techniques
Haycock, J. W. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-60761-984-0_1 · Cited by 534
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507 · cited 2×
“Cytokines are used in combination therapies to inhibit response to anticancer monoclonal antibodies targeting TME (the clinical applications of cytokines for cancer immunotherapy is extensively reviewed in [107]).”
BackgroundZhou, Y., Ren, H., Dai, B., Li, J., Shang, L., Huang, J., & Shi, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0965-2 · Cited by 456
Induction of heat shock proteins in B-cell exosomes
Clayton, A., Turkes, A., Navabi, H., Mason, M. D., & Tabi, Z. (2005) · Journal of Cell Science · doi:10.1242/jcs.02494 · Cited by 454
Tumor and its microenvironment: A synergistic interplay
Catalano, V., Turdo, A., Di Franco, S., Dieli, F., Todaro, M., & Stassi, G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.007 · Cited by 444
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Barnes, T. A., & Amir, E. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.220 · Cited by 432
Advances in structure-based drug discovery of carbonic anhydrase inhibitors
Supuran, C. T. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1253677 · Cited by 413
The role of exosomes in cancer metastasis
Steinbichler, T. B., Dudás, J., Riechelmann, H., & Skvortsova, I.-I. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.006 · Cited by 389
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship
Netea-Maier, R. T., Smit, J. W. A., & Netea, M. G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.037 · Cited by 326
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
Shirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Lamberts, L. E., Koch, M., de Jong, J. S., Adams, A. L. L., Glatz, J., Kranendonk, M. E. G., Terwisscha van Scheltinga, A. G. T., Jansen, L., de Vries, J., Lub-de Hooge, M. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0437 · Cited by 285
Advanced Cell Culture Techniques for Cancer Drug Discovery
Lovitt, C., Shelper, T., & Avery, V. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 282
MMP-Responsive ‘Smart’ Drug Delivery and Tumor Targeting
Yao, Q., Kou, L., Tu, Y., & Zhu, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.003 · Cited by 280
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors
Supuran, C. T. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1548608 · Cited by 252
Ritchie, J. P., Ramani, V. C., Ren, Y., Naggi, A., Torri, G., Casu, B., Penco, S., Pisano, C., Carminati, P., Tortoreto, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2476 · Cited by 250
The role of the myofibroblast in tumor stroma remodeling
Otranto, M., Sarrazy, V., Bonté, F., Hinz, B., Gabbiani, G., & Desmouliere, A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20377 · Cited by 250
Exosome in Tumour Microenvironment: Overview of the Crosstalk between Normal and Cancer Cells
Roma-Rodrigues, C., Fernandes, A. R., & Baptista, P. V. (2014) · BioMed Research International · doi:10.1155/2014/179486 · Cited by 245
Self-citationThe significance of intertumor and intratumor heterogeneity in liver cancer
Liu, J., Dang, H., & Wang, X. W. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.165 · Cited by 244
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 242
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors
Supuran, C. T. (2017) · Metabolites · doi:10.3390/metabo7030048 · Cited by 232
Koumangoye, R. B., Sakwe, A. M., Goodwin, J. S., Patel, T., & Ochieng, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024234 · Cited by 227
Overview on Clinical Relevance of Intra-Tumor Heterogeneity
Stanta, G., & Bonin, S. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00085 · Cited by 224
Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0137 · Cited by 214
IL-1 drives breast cancer growth and bone metastasis in vivo
Holen, I., Lefley, D. V., Francis, S. E., Rennicks, S., Bradbury, S., Coleman, R. E., & Ottewell, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12289 · Cited by 210
3D tumor models: History, advances and future perspectives
Benien, P., & Swami, A. (2014) · Future Oncology · doi:10.2217/fon.13.274 · Cited by 208
Characterization of Uptake and Internalization of Exosomes by Bladder Cancer Cells
Franzen, C. A., Simms, P. E., Van Huis, A. F., Foreman, K. E., Kuo, P. C., & Gupta, G. N. (2014) · BioMed Research International · doi:10.1155/2014/619829 · Cited by 204
Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH
Taraboletti, G., D'Ascenzoy, S., Giusti, I., Marchetti, D., Borsotti, P., Millimaggi, D., Giavazzi, R., Pavan, A., & Dolo, V. (2006) · Neoplasia · doi:10.1593/neo.05583 · Cited by 199
Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)
Nocentini, A., & Supuran, C. T. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1508453 · Cited by 197
Harlaar, N. J., Koller, M., de Jongh, S. J., van Leeuwen, B. L., Hemmer, P. H., Kruijff, S., van Ginkel, R. J., Been, L. B., de Jong, J. S., Kats-Ugurlu, G., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30082-6 · Cited by 197
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 196
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
Tahmasebi Birgani, M., & Carloni, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020405 · Cited by 193
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 191
The role of IL-1B in breast cancer bone metastasis
Tulotta, C., & Ottewell, P. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0309 · Cited by 191
Microfluidic 3D models of cancer
Sung, K. E., & Beebe, D. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.002 · Cited by 190
Progress and Perspectives in the Chemotherapy of Acute Leukemia
FREI, E., & FREIREICH, E. J. (1965) · Advances in Chemotherapy · doi:10.1016/b978-1-4831-9930-6.50011-3 · Cited by 185
Capello, M., Vykoukal, J. V., Katayama, H., Bantis, L. E., Wang, H., Kundnani, D. L., Aguilar-Bonavides, C., Aguilar, M., Tripathi, S. C., Dhillon, D. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08109-6 · Cited by 179
Three-dimensional in vitro cancer models: a short review
Wang, C., Tang, Z., Zhao, Y., Yao, R., Li, L., & Sun, W. (2014) · Biofabrication · doi:10.1088/1758-5082/6/2/022001 · Cited by 173
Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R., & Skardal, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21200-8 · Cited by 167
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Rai, A., Greening, D. W., Chen, M., Xu, R., Ji, H. L., & Simpson, R. J. (2018) · PROTEOMICS · doi:10.1002/pmic.201800148 · Cited by 164
Aleman, J., & Skardal, A. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26871 · Cited by 160
Scannevin, R. H., Alexander, R., Haarlander, T. M., Burke, S. L., Singer, M., Huo, C., Zhang, Y.-M., Maguire, D., Spurlino, J., Deckman, I., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806075 · Cited by 160
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site
Singh, S., Lomelino, C. L., Mboge, M. Y., Frost, S. C., & McKENNA, R. V. (2018) · Molecules · doi:10.3390/molecules23051045 · Cited by 159
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
The potential role of leptin in tumor invasion and metastasis
Ray, A., & Cleary, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.11.002 · Cited by 158
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Hamberg, P., Verweij, J., & Sleijfer, S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0274 · Cited by 155
Membrane-type matrix metalloproteases as diverse effectors of cancer progression
Turunen, S. P., Tatti-Bugaeva, O., & Lehti, K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.002 · Cited by 154
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 154
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 153
Cancer Energy Metabolism: Shutting Power off Cancer Factory
Kim, S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.184 · Cited by 152
Graner, M. W., Cumming, R. I., & Bigner, D. D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3588-07.2007 · Cited by 150
Tumor Microenvironment: A New Treatment Target for Cancer
Tsai, M., Chang, W., Huang, M., & Kuo, P. (2014) · ISRN Biochemistry · doi:10.1155/2014/351959 · Cited by 148
Vaupel, P. W., & Mayer, A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0620-8_3 · Cited by 147
Designer combination therapy for cancer
Lane, D. P. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-163 · Cited by 145
Lu, S., Cuzzucoli, F., Jiang, J., Liang, L.-G., Wang, Y., Kong, M., Zhao, X., Cui, W., Li, J., & Wang, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00852c · Cited by 144
Targeting myeloid cells in the tumor sustaining microenvironment
Schupp, J., Krebs, F. K., Zimmer, N., Trzeciak, E. R., Schuppan, D., & Tuettenberg, A. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.013 · Cited by 142
Moraes, L. A., Kar, S., Foo, S. L., Gu, T., Toh, Y. Q., Ampomah, P. B., Sachaphibulkij, K., Yap, G. L. R., Zharkova, O., Lukman, H. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17622-5 · Cited by 142
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A., Giebel, B., Schadendorf, D., & Paschen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28168 · Cited by 136
Cancer metabolism: New insights into classic characteristics
Kato, Y., Maeda, T., Suzuki, A., & Baba, Y. (2017) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2017.08.003 · Cited by 132
Rivera‐Cruz, C. M., Shearer, J. J., Neto, M. F., & Figueiredo, M. L. (2017) · Stem Cells International · doi:10.1155/2017/4015039 · Cited by 129
Molecular mechanisms underlying therapeutic potential of pericytes
Harrell, C. R., Marković, B. S., Fellabaum, C., Arsenijević, A., Djonov, V., & Volarević, V. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0423-7 · Cited by 129
Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Patel, S., & Player, M. R. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789007327 · Cited by 128
Applications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Cancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127
Relaxin Promotes Prostate Cancer Progression
Feng, S., Agoulnik, I. U., Bogatcheva, N. V., Kamat, A. A., Kwabi‐Addo, B., Li, R., Ayala, G., Ittmann, M., & Agoulnik, A. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2492 · Cited by 127
Mardhian, D. F., Storm, G., Bansal, R., & Prakash, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.031 · Cited by 123
Evaluating Biomaterial- and Microfluidic-Based 3D Tumor Models
Carvalho, M. R., Lima, D., Reis, R. L., Correlo, V. M., & Oliveira, J. M. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.09.009 · Cited by 122
Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach
Adjei, I. M., & Sharma, B. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6010081 · Cited by 117
Mendes, R. G. P. R., Fernandes, A. R., & Baptista, P. V. (2017) · Genes · doi:10.3390/genes8030094 · Cited by 113
Self-citationDrug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs
Santo, V. E., Rebelo, S. P., Estrada, M. F., Alves, P. M., Boghaert, E. R., & Brito, C. (2016) · Biotechnology Journal · doi:10.1002/biot.201600505 · Cited by 112
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 112
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 110
Therapeutic implications of tumor interstitial acidification
Kolosenko, I., Avnet, S., Baldini, N., Viklund, J., & Milito, A. D. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.008 · Cited by 109
Probing the relevance of 3D cancer models in nanomedicine research
Leong, D. T., & Ng, K. W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.007 · Cited by 104
Tissue-engineered models of human tumors for cancer research
Villasante, A., & Vunjak‐Novakovic, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1009442 · Cited by 103
Coulson, R. S., Liew, S. H., Connelly, A. A., Yee, N. S., Deb, S., Kumar, B., Vargas, A. C., O'Toole, S. A., Parslow, A. C., Poh, A. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15553 · Cited by 103
Chen, T., Li, Q., Liu, Z., Chen, Y., Feng, F., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.044 · Cited by 102
The role of macrophage phenotype in regulating the response to radiation therapy
Shi, X., & Shiao, S. L. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.002 · Cited by 102
Metabolic features of macrophages in inflammatory diseases and cancer
Na, Y. R., Je, S., & Seok, S. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.044 · Cited by 101
Lipson, E. J., Sharfman, W. H., Chen, S., McMiller, T. L., Pritchard, T. S., Salas, J. T., Sartorius-Mergenthaler, S., Freed, I., Ravi, S., Wang, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0572-3 · Cited by 100
MMP1 and MMP3 Polymorphisms in Promoter Regions and Cancer
Biondi, M. L., Turri, O., Leviti, S., Seminati, R., Cecchini, F., Bernini, M., Ghilardi, G., & Guagnellini, E. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2023 · Cited by 95
Targeting hypoxic response for cancer therapy
Paolicchi, E., Gemignani, F., Krstic–Demonacos, M., Dedhar, S., Mutti, L., & Landi, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7229 · Cited by 94
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
Sgambato, A., Casaluce, F., Maione, P., & Gridelli, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1412260 · Cited by 93
Ling, B., Watt, K., Banerjee, S., Newsted, D., Truesdell, P., Adams, J., Sidhu, S. S., & Craig, A. W. B. (2017) · Oncotarget · doi:10.18632/oncotarget.17702 · Cited by 92
Tumor-derived exosomes, microRNAs, and cancer immune suppression
Graner, M. W., Schnell, S. M., & Olin, M. R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0689-6 · Cited by 92
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Duchnowska, R., Loibl, S., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.004 · Cited by 90
Tumor Microenvironment on a Chip: The Progress and Future Perspective
Ahn, J., Sei, Y. J., Jeon, N. L., & Kim, Y. (2017) · Bioengineering · doi:10.3390/bioengineering4030064 · Cited by 83
Cassinelli, G., Lanzi, C., Tortoreto, M., Cominetti, D., Petrangolini, G., Favini, E., Zaffaroni, N., Pisano, C., Penco, S., Vlodavsky, I., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.023 · Cited by 82
Heparanase in inflammation and inflammation‐associated cancer
Meirovitz, A., Goldberg, R. L., Gallimidi, A. B., Rubinstein, A. M., Hermano, E., & Elkin, M. (2013) · FEBS Journal · doi:10.1111/febs.12184 · Cited by 81
Fernandes, A. R., de Jesus, J. T. C. L., Martins, P. H. D. F., Figueiredo, S., Rosa, D., Martins, L. M. D. R. S., Corvo, M. L., Carvalheiro, M. C., Costa, P. M., & Baptista, P. V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.021 · Cited by 81
Self-citationOrgan-Tumor-on-a-Chip for Chemosensitivity Assay: A Critical Review
Kashaninejad, N., Nikmaneshi, M., Moghadas, H., Kiyoumarsi Oskouei, A., Rismanian, M., Barisam, M., Saidi, M., & Firoozabadi, B. (2016) · Micromachines · doi:10.3390/mi7080130 · Cited by 79
Nanomedicines Targeting the Tumor Microenvironment
Tong, R., & Langer, R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000123 · Cited by 79
Exosome-Mediated Signaling in Epithelial to Mesenchymal Transition and Tumor Progression
Conigliaro, A., & Cicchini, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010026 · Cited by 78
Kumar, V., & Varghese, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801198 · Cited by 76
Roma‐Rodrigues, C., Raposo, L. R., Cabral, R. M., Paradinha, F., Baptista, P. V., & Fernandes, A. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010162 · Cited by 76
Self-citationPeptide-coated gold nanoparticles for modulation of angiogenesis in vivo
Baptista, P. V., Kanaras, A. G., Heuer‐Jungemann, A., Roma‐Rodrigues, C., & Fernandes, A. R. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s108661 · Cited by 73
Self-citationYang, Z., Yang, X., Xu, S., Jin, P., Li, X., Xiao, W., Liu, D., Huang, K., Long, S., Wang, Y., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0732-6 · Cited by 71
Exosomes in cancer therapy: a novel experimental strategy.
Gao, D., & Jiang, L. (2018) · Europe PMC (PubMed Central) · Cited by 69
Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
Ikemura, K., Hiramatsu, S., & Okuda, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00911 · Cited by 67
Siegler, E. L., Kim, Y. J., & Wang, P. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.08.002 · Cited by 65
Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy
Iessi, E., Logozzi, M., Mizzoni, D., Raimo, R. D., Supuran, C. T., & Fais, S. (2017) · Metabolites · doi:10.3390/metabo8010002 · Cited by 65
Microfluidic modeling of the biophysical microenvironment in tumor cell invasion
Huang, Y., Segall, J. E., & Wu, M. (2017) · Lab on a Chip · doi:10.1039/c7lc00623c · Cited by 63
Wang, J., He, X., Yao, N., Liang, W. J., & Zhang, Y. C. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/417894 · Cited by 63
Intra‐tumor heterogeneity in head and neck cancer and its clinical implications
Mroz, E. A., & Rocco, J. W. (2016) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2016.05.007 · Cited by 63
Smuggling gold nanoparticles across cell types – A new role for exosomes in gene silencing
Roma‐Rodrigues, C., Pereira, F. B., Matos, A., Fernandes, M. B., Baptista, P. V., & Fernandes, A. R. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.01.013 · Cited by 62
Self-citationPujada, A., Walter, L., Patel, A. R., Bui, T. A., Zhang, Z., Zhang, Y., Denning, T. L., & Garg, P. (2017) · Oncotarget · doi:10.18632/oncotarget.21841 · Cited by 62
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets
Szebeni, G. J., Vízler, C., Nagy, L. I., Kitajka, K., & Puskás, L. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111958 · Cited by 61
Willumsen, N., Thomsen, L. B., Bager, C. L., Jensen, C., & Karsdal, M. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2074-z · Cited by 60
The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth
Wang, S., Lu, J., You, Q., Huang, H., Chen, Y., & Liu, K. (2016) · Oncotarget · doi:10.18632/oncotarget.10756 · Cited by 59
Chu, Q., Forouzesh, B., Syed, S. K., Mita, M. M., Schwartz, G. H., Copper, J., Curtright, J., & Rowinsky, E. K. (2007) · Investigational New Drugs · doi:10.1007/s10637-006-9031-6 · Cited by 58
The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation
Trivanović, D. I., Krstić, J., Djordjević, I. O., Mojsilović, S. B., Santibanez, J. F., Bugarski, D. S., & Jauković, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/7314016 · Cited by 56
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53
Imaging the Tumor Microenvironment
Abadjian, M.-C. Z., Edwards, W. B., & Anderson, C. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_15 · Cited by 49
Tumor-associated myeloid cells as guiding forces of cancer cell stemness
Sica, A., Porta, C., Amadori, A., & Pastò, A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1997-8 · Cited by 48
GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer
Nemunaitis, J. J. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00210-4 · Cited by 45
Mangiameli, D. P., Blansfield, J., Kachala, S., Lorang, D., Schafer, P. H., Muller, G. W., Stirling, D., & Libutti, S. K. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-38 · Cited by 44
Exosome mediated multidrug resistance in cancer.
Yousafzai, N. A., Wang, H., Wang, Z., Zhu, Y., Zhu, L., Jin, H., & Wang, X. (2018) · Europe PMC (PubMed Central) · Cited by 44
Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction
Boohaker, R. J., Sambandam, V., Segura, I., Miller, J., Suto, M. J., & Xu, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.031 · Cited by 43
Lamprecht, S. A., Sigal-Batikoff, I., Shany, S., Abu‐Freha, N., Ling, E., Delinasios, G. J., Moyal-Atias, K., Delinassios, J. G., & Fich, A. (2018) · Cancers · doi:10.3390/cancers10030061 · Cited by 43
Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Herrmann, J. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0514-0 · Cited by 43
Busby, J., McMenamin, Ú. C., Spence, A. D., Johnston, B. T., Hughes, C., & Cardwell, C. R. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14388 · Cited by 43
Zhao, B., Zhao, H., & Zhao, J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0421-z · Cited by 43
Ishii, N., Araki, K., Yokobori, T., Hagiwara, K., Gantumur, D., Yamanaka, T., Handa, T., Tsukagoshi, M., Igarashi, T., Watanabe, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13847 · Cited by 41
Remigis, A. D., de Gruijl, T. D., Uram, J. N., Tzou, S.-C., Iwama, S., Talor, M. V., Armstrong, T. D., Santegoets, S. J. A. M., Slovin, S. F., Zheng, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28973 · Cited by 40
Sauter, E. R. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.08.13 · Cited by 38
Mechanisms regulating immune surveillance of cellular stress in cancer
Seelige, R., Searles, S. C., & Bui, J. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2597-7 · Cited by 36
Clark, D. P. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21951 · Cited by 36
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
Falco, V. D., Carlomagno, F., Li, H., & Santoro, M. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.04.013 · Cited by 36
In Vivo Imaging of Pro- and Antitumoral Cellular Components of the Tumor Microenvironment
Helfen, A., Roth, J., Ng, T., & Eisenblätter, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198952 · Cited by 35
Noda, S., Yoshida, T., Hira, D., Murai, R., Tomita, K., Tsuru, T., Kageyama, S., Kawauchi, A., Ikeda, Y., Morita, S., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.001 · Cited by 34
Aparicio, L. M. A., Fernandez, I. P., & Cassinello, J. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1657-7 · Cited by 33
Таширева, Л. А., Михайлович, П. В., Манских, В. Н., Denisov, E. V., Savelieva, O. E., Кайгородова, Е. В., & Zavyalova, M. V. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917050029 · Cited by 30
Tumor-on-a-chip platforms for assessing nanoparticle-based cancer therapy
Wang, Y., Cuzzucoli, F., Escobar, A., Lu, S., Liang, L., & Wang, S. (2018) · Nanotechnology · doi:10.1088/1361-6528/aac7a4 · Cited by 29
Myofibroblasts in oral potentially malignant disorders: Is it related to malignant transformation?
Coletta, R. D., & Salo, T. A. (2018) · Oral Diseases · doi:10.1111/odi.12694 · Cited by 29
Comparison of functional limbal epithelial stem cell isolation methods
López‐Paniagua, M., Nieto-Miguel, T., de la Mata, A., Dziasko, M. A., Galindo, S., Rey, E., Herreras, J. M., Corrales, R. M., Daniels, J. T., & Calonge, M. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.12.002 · Cited by 28
Zhou, Z., Ma, X., Wang, F., Sun, L., & Zhang, G. (2018) · Disease Markers · doi:10.1155/2018/7565834 · Cited by 27
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
Ntanasis‐Stathopoulos, I., Fotopoulos, G., Tzanninis, I., & Kotteas, E. A. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1206117 · Cited by 22
Gu, Y., Lee, H., Golub, L. M., Sorsa, T. A., Konttinen, Y. T., & Simon, S. R. (2005) · Annals of Medicine · doi:10.1080/07853890500300386 · Cited by 22
Nakano, K., Funauchi, Y., Hayakawa, K., Tanizawa, T., Ae, K., Matsumoto, S., & Takahashi, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010060 · Cited by 20
Kitano, H., Kitadai, Y., Teishima, J., Yuge, R., Shinmei, S., Goto, K., Inoue, S., Hayashi, T., Sentani, K., Yasui, W., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1124 · Cited by 18
Li, J., & Gu, J. H. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2299-y · Cited by 15
Research works printed but not linked: 1
- Larson, 2015, 3D cell culture: A review of current techniques, BioTek, 6, 1
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Metadata
- Authors
- Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R.
- Affiliations
- UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa. Campus de Caparica, 2829-516 Caparica, Portugal
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Baptista, Pedro V.
- Fernandes, Alexandra R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 840
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6413095
- OpenAlex
- W2913062750
- Cited by
- 1,187
- References
- 212
- Citations by year
- 2026: 76 · 2025: 134 · 2024: 156 · 2023: 229 · 2022: 186 · 2021: 216 · 2020: 139 · 2019: 47
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Ministério da Ciência, Tecnologia e Ensino Superior (UID/Multi/04378/2019, SFRH/BPD/124612/2016)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- tumor microenvironment, cancer therapy, Warburg effect, tumor hypoxia, oxidative stress, extracellular matrix, tumor stromal cells, tumor-associated macrophages, angiogenesis, metastasis, exosomes, nanomedicine, combination therapy, tumor models, tumor-on-a-chip, tumor spheroids
- MeSH terms
- Animals, Humans, Models, Biological, Neoplasms, Neovascularization, Pathologic, Nanomedicine, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.